Takeaway
Amyloid-beta (Aβ) peptides in the plasma could be a reliable biomarker for discriminating Aβ- positron emission tomography (PET) status to facilitate screening for prodromal Alzheimer’s disease (AD) clinical trials.
Why this matters
Healthy people at risk of AD are needed for clinical trials of preventative therapies.
These people are difficult to identify owing to lack of amyloid-beta positive PET scan, highlighting a need for accessible and inexpensive screening tools.